Chronic Inflammatory Disease

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Centessa Pharmaceuticals
1 program
1
CBS001Phase 11 trial
Active Trials
NCT05323110TerminatedEst. Aug 2023
Precision BioSciences
1 program
Biobanking with genetic analysisN/A1 trial
Active Trials
NCT04334031Recruiting2,200Est. Jul 2031

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Centessa PharmaceuticalsCBS001
Precision BioSciencesBiobanking with genetic analysis

Clinical Trials (2)

Total enrollment: 2,200 patients across 2 trials

Study of Intravenously Administered Anti-LIGHT Monoclonal Antibody CBS001 in Healthy Volunteers

Start: Apr 2022Est. completion: Aug 2023
Phase 1Terminated
NCT04334031Precision BioSciencesBiobanking with genetic analysis

Deployment o the Multidisciplinary Prospective Cohort Imminent

Start: Jul 2020Est. completion: Jul 20312,200 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 2,200 patients
2 companies competing in this space